Foralumab ( DrugBank: Foralumab )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1
96	クローン病	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05029609 (ClinicalTrials.gov)	October 2021	27/8/2021	Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS	A Phase 1b, Double-Blind, Randomized, Placebo Controlled, Multiple Ascending Dose Study of the Safety, Tolerability and Immune Effects of the Intranasal Anti-CD3 Monoclonal Antibody Foralumab in Primary and Secondary Progressive MS	Primary Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Multiple Sclerosis	Drug: Intranasal Foralumab Solution;Drug: Placebo	Tiziana Life Sciences, PLC	NULL	Not yet recruiting	25 Years	70 Years	All	55	Phase 1	NULL

96. クローン病

---

臨床試験数 : 2,442 /  薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05028946 (ClinicalTrials.gov)	May 1, 2022	24/8/2021	A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease	A Phase IB Multiple Ascending Dose Study of Safety and Tolerability of Orally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Subjects With Moderate to Severely Active Crohn's Disease	Crohn's Disease	Drug: Foralumab	Tiziana Life Sciences, PLC	NULL	Withdrawn	18 Years	70 Years	All	0	Phase 1	NULL